Publications by authors named "Jonathan Oliner"

Claim this Profile
R
Restoration of the Tumor Suppressor Function of Y220C-Mutant p53 by Rezatapopt, a Small-Molecule Reactivator.
Anna M Puzio-Kuter, Lizhong Xu, Mary Kate McBrayer, Romyr Dominique, Hongju H Li, Jonathan D Oliner

Cancer Discov· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Label-free fluorescence lifetime imaging for the assessment of cell viability in living tumor fragments.
Jason T Smith, Chao J Liu, Jeannine Degnan, Jonathan N Ouellette, Matthew W Conklin, Jonathan D Oliner

J Biomed Opt· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing cell viability with dynamic optical coherence microscopy.
Chao J Liu, Jason T Smith, Yuanbo Wang, Jonathan N Ouellette, Jeremy D Rogers, Jonathan D Oliner

Biomed Opt Express· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of MDM2 Amplification and Overexpression in Tumorigenesis.
Jonathan D Oliner, Anne Y Saiki, Sean Caenepeel

Cold Spring Harb Perspect Med· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying the determinants of response to MDM2 inhibition.
Anne Y Saiki, Sean Caenepeel, Elissa Cosgrove, Cheng Su, Michael Boedigheimer, Jonathan D Oliner

Oncotarget· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.
Jude Canon, Tao Osgood, Steven H Olson, Anne Y Saiki, Rebecca Robertson, Jonathan D Oliner

Mol Cancer Ther· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interaction.
Yosup Rew, Daqing Sun, Xuelei Yan, Hilary P Beck, Jude Canon, Jonathan D Oliner

J Med Chem· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antagonism of Ang-Tie2 and Dll4-Notch signaling has opposing effects on tumor endothelial cell proliferation, evidenced by a new flow cytometry method.
Marc Payton, Toni Jun, William Wayne, Dongyin Yu, Raffi Manoukian, Jonathan Oliner

Lab Invest· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization beyond AMG 232: discovery and SAR of sulfonamides on a piperidinone scaffold as potent inhibitors of the MDM2-p53 protein-protein interaction.
Yingcai Wang, Jiang Zhu, Jiwen Jim Liu, Xiaoqi Chen, Jeff Mihalic, Jonathan D Oliner

Bioorg Med Chem Lett· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Potent and Simplified Piperidinone-Based Inhibitors of the MDM2-p53 Interaction.
Ming Yu, Yingcai Wang, Jiang Zhu, Michael D Bartberger, Jude Canon, Jonathan D Oliner

ACS Med Chem Lett· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.
Ana Z Gonzalez, Zhihong Li, Hilary P Beck, Jude Canon, Ada Chen, Jonathan D Oliner

J Med Chem· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways.
Anne Y Saiki, Sean Caenepeel, Dongyin Yu, Julie A Lofgren, Tao Osgood, Jonathan D Oliner

Oncotarget· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interaction.
Ana Z Gonzalez, John Eksterowicz, Michael D Bartberger, Hilary P Beck, Jude Canon, Jonathan D Oliner

J Med Chem· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.
Daqing Sun, Zhihong Li, Yosup Rew, Michael Gribble, Michael D Bartberger, Jonathan D Oliner

J Med Chem· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational design and binding mode duality of MDM2-p53 inhibitors.
Felix Gonzalez-Lopez de Turiso, Daqing Sun, Yosup Rew, Michael D Bartberger, Hilary P Beck, Jonathan D Oliner

J Med Chem· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design of novel inhibitors of the MDM2-p53 interaction.
Yosup Rew, Daqing Sun, Felix Gonzalez-Lopez De Turiso, Michael D Bartberger, Hilary P Beck, Jonathan D Oliner

J Med Chem· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, inhibits angiogenesis in models of ocular neovascular diseases.
Jonathan D Oliner, James Bready, Linh Nguyen, Juan Estrada, Eunju Hurh

Invest Ophthalmol Vis Sci· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement of the synthesis and pharmacokinetic properties of chromenotriazolopyrimidine MDM2-p53 protein-protein inhibitors.
Hilary P Beck, Michael DeGraffenreid, Brian Fox, John G Allen, Yosup Rew, Jonathan D Oliner

Bioorg Med Chem Lett· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody.
Angela Coxon, James Bready, Hosung Min, Stephen Kaufman, Juan Leal, Jonathan D Oliner

Mol Cancer Ther· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth.
Hiroya Hashizume, Beverly L Falcón, Takashi Kuroda, Peter Baluk, Angela Coxon, Jonathan D Oliner

Cancer Res· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels.
Beverly L Falcón, Hiroya Hashizume, Petros Koumoutsakos, Jeyling Chou, James V Bready, Jonathan D Oliner

Am J Pathol· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction.
John G Allen, Matthew P Bourbeau, G Erich Wohlhieter, Michael D Bartberger, Klaus Michelsen, Jonathan D Oliner

J Med Chem· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.
Roy S Herbst, David Hong, Linnea Chap, Razelle Kurzrock, Edward Jackson, Jonathan D Oliner

J Clin Oncol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2.
Jonathan Oliner, Hosung Min, Juan Leal, Dongyin Yu, Shashirekha Rao

Cancer Cell· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction of BAIAP3 by the EWS-WT1 chimeric fusion implicates regulated exocytosis in tumorigenesis.
Rachel E Palmer, Sean Bong Lee, Jenise C Wong, Paul A Reynolds, Hong Zhang, Jonathan D Oliner

Cancer Cell· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis